Current view of Helicobacter pylori
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.9889Keywords:
Helicobacter pylori, terapies, gastric cancer, microbiotaAbstract
Helicobacter pylori infects more than 50% of the world population and is the main risk factor associated with gastric cancer. The carcinogenic cascade and the factors widely related to itself, for which reason eradication therapies have had a significant impact on the incidence of this disease, achieving a more significant decrease in those populations without the presence of premalignant lesions, which conveyed great value to medical management as part of primary prevention of this oncological pathology. The therapies aimed at its eradication are not universal or unique and depend to a great extent on the local epidemiology and the molecular characteristics of the microorganism, for which the genetic susceptibility tests open an important path in the treatment of these diseases, taking into account that the population studies carried out internationally with a view to carrying out an appropriate treatment scheme lose validity in the absence of local knowledge about the disease and require more research in this regard. Taking into account the low availability of susceptibility tests and their non-cost-effectiveness, various lines of treatment have been implemented in H. pylori infection based on local resistance levels that allow guiding the appropriate pharmacological treatment for the disease. operated patient.
Downloads
References
Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017; 22(Suppl 1). doi: 10.1111/hel.12405.
Hooi J, Lai WY, Ng WK, Suen M, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017; 153(2): 420-429. Doi: 10.1053/j.gastro.2017.04.022
Sepulveda M, Maldonado C, Bravo J, Satizabal N, Gempeler A, et al. Prevalencia de Helicobacter pylori en pacientes llevados a endoscopia de vías digestivas altas en un hospital de referencia en Cali, Colombia, en 2020. Rev Colomb Gastroenterol. 2022; 37(4), 355-361. Doi: 10.22516/25007440.868
Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999; 94(9): 2373-2379. Doi: 10.1111/j.1572-0241.1999.01360.x
McNicholl AG, O'Morain CA, Megraud F, Gisbert JP.Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter. 2019; 24(5): e12630. Doi: 10.1111/hel.12630
Bordin DS, Embutnieks YV, Vologzhanina LG, Il'chishina TA, Voinovan IN, Sarsenbaeva AS, et al. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. Terapevticheskii arkhiv. 2018; 90(2): 35-42. Doi: 10.26442/terarkh201890235-42
Rodriguez-Castro KI, Franceschi M, Noto A, Miraglia C, Nouvenne A, Leandro G, et al. Clinical manifestations of chronic atrophic gastritis. Acta bio-medica : Atenei Parmensis. 2018; 89(8-S): 88-92. Doi: 10.23750/abm.v89i8-S.7921
González CA, Pardo ML, Ruiz LJM, Alonso P, Bonet C, Garcia RM, et al. Gastric cancer occurrence in preneoplastic lesions: A long-term follow-up in a high-risk area in Spain. Int J Cancer 2010; 127: 2654-60. DOI: 10.1002/ijc.25273.
Organización Mundial de la Salud. Agencia Internacional de Investigación en Cáncer. GLOBOCAN; 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf
Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterol. 2007; 133(2), 659-672.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M,et al. Helicobacter pylori infection and the development of gastric cancer. New Engl J Med. 2001; 345(11): 784-789. Doi: 10.1056/NEJMoa001999
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterol. 2016; 150(5): 1113-1124.e5. Doi: 10.1053/j.gastro.2016.01.028
Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk Factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020; 158(3): 527-536.e7. Doi: 10.1053/j.gastro.2019.10.019
Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, You J, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022; 163(1): 154-162.e3. Doi: 10.1053/j.gastro.2022.03.039
Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020; 69(9): 1598-1607. Doi: 10.1136/gutjnl-2019-319696
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; gutjnl-2022-327745. Doi: 10.1136/gutjnl-2022-327745
Hanafiah A, Lopes BS. Genetic diversity and virulence characteristics of Helicobacter pylori isolates in different human ethnic groups. Infect Genet Evol. 2020; 78: 104135. Doi: 10.1016/j.meegid.2019.104135
Nyssen OP, Vaira D, Pérez AÁ, Rodrigo L, Castro-Fernandez M, Jonaitis L, et al. Empirical second-line therapy in 5000 patients of the european registry on Helicobacter pylori management (Hp-EuReg). Clinical Gastroenterol Hepatol. 2022; 20(10): 2243-2257. Doi: 10.1016/j.cgh.2021.12.025
Morcillo J, Otero W, Gómez M. Helicobacter pylori: ¿cómo mejorar las terapias de erradicación?. Rev Colomb Gastroenterol. 2018; 33: 437. Doi: 10.22516/25007440.314.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5): 646-64. doi: 10.1136/gutjnl-2012-302084
Molina J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014; 20(30): 10338-47. doi: 10.3748/wjg.v20.i30.10338
Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013; 12: CD008337. doi: 10.1002/14651858.CD008337.pub2
Otero W, Trespalacios AA, Otero L, Vallejo M, Torres M, Pardo R, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015; 30(Suppl 1): 17-33
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212-39. doi: 10.1038/ajg.2016.563.
Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018; 16(9): 679-687. Doi: 10.1080/14787210.2018.1511427
Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Medica. 2021; 112(2): 281-287. Doi: 10.23736/S0026-4806.20.06810-X
Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter. 2022; 27(1): e12860. doi: 10.1111/hel.12860
Jaramillo-Trujillo G, Otero-Regino WA, Camacho-Montaño AM, Estrada-Orozco KP. Efficacy and safety of using probiotics as adjuvants in the eradication of Helicobacter pylori. Systematic review and meta-analysis. Rev Fac Med 2023; 71(2): e98018. doi: 10.15446/revfacmed.v71n2.98018.
Downloads
Published
Versions
- 2022-12-30 (2)
- 2022-12-30 (1)
Issue
Section
License
Copyright (c) 2022 Interdisciplinary Journal of Epidemiology and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
